skip to main content
Idioma:

Diffuse Large B-cell Lymphoma Presenting as Bilateral Renal Masses: Successful Treatment with Dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy Regimen

Kaur, Anahat ; Abughanimeh, Omar ; Zafar, Yousaf ; Pluard, Timothy

Curēus (Palo Alto, CA), 2019-01, Vol.11 (1), p.e3814 [Periódico revisado por pares]

United States: Cureus Inc

Texto completo disponível

Citações Citado por
  • Título:
    Diffuse Large B-cell Lymphoma Presenting as Bilateral Renal Masses: Successful Treatment with Dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy Regimen
  • Autor: Kaur, Anahat ; Abughanimeh, Omar ; Zafar, Yousaf ; Pluard, Timothy
  • Assuntos: Abdomen ; Bone marrow ; Chemotherapy ; Drug dosages ; Family medical history ; Immunotherapy ; Internal Medicine ; Kidneys ; Lymphatic system ; Lymphoma ; Medical imaging ; Medical prognosis ; Monoclonal antibodies ; Oncology ; Patients ; Radiation therapy ; Targeted cancer therapy ; Tumors
  • É parte de: Curēus (Palo Alto, CA), 2019-01, Vol.11 (1), p.e3814
  • Descrição: Diffuse large B-cell lymphoma (DLBL) is an aggressive type of non-Hodgkin lymphoma (NHL). Renal involvement in NHL is not uncommon in advanced stages; however, it is rare to have kidneys affected early in the course of the disease. Usual chemotherapy regimen for DLBL is rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (R-CHOP). This is a case of a 50-year-old female diagnosed with DLBL who presented with bilateral renal involvement at disease onset and also underwent complete remission after six cycles of dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (DA-REPOCH). Limited data exist on outcomes of patients with DLBL and renal disease who are treated with high-intensity regimes such as DA-REPOCH. It would be worth looking further into outcomes of DLBL patients especially with renal involvement on DA-REPOCH. Multicenter trials are required to demonstrate which of the two chemotherapy regimens (R-CHOP vs. DA-REPOCH) have better progression-free survival in this particular subset of patients.
  • Editor: United States: Cureus Inc
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.